Hob Biotech: The company's price-to-earnings ratio is significantly higher than the industry average

Hob Biotech issued an announcement regarding abnormal fluctuations, stating that the cumulative price deviation of the company's stock closing price has reached 30% over three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. After the company's self-examination and verification with the controlling shareholder and actual controller, there is no significant information that should be disclosed but has not been disclosed. As of June 12, 2025, the company's closing price was 137.88 yuan per share, with the latest price-to-earnings ratio at 236.24 times and the rolling price-to-earnings ratio at 251.04 times. The average rolling price-to-earnings ratio for the pharmaceutical manufacturing industry over the past month is 28.07 times. The company particularly reminds investors to pay attention to investment risks, make rational decisions, and invest prudently